Can an Iron-Binding drug protect the brain after a severe stroke?

NCT ID NCT04566991

Recruiting now Disease control Sponsor: Aditya S. Pandey, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tests whether deferoxamine, a drug that binds excess iron, can reduce brain injury after aneurysmal subarachnoid hemorrhage (aSAH), a severe stroke with high death and disability rates. About 120 participants will receive one of two doses of deferoxamine or a placebo within 24 hours of symptoms. Researchers will track recovery and cognitive function for up to 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Deferoxamine (also known as Desferal)
What this could lead to: If it works, this could point toward a treatment that reduces brain damage and improves recovery after a severe type of stroke called aneurysmal subarachnoid hemorrhage.
What could go wrong: This is an early Phase 2 trial with only 120 people, so results may not apply to everyone. The drug may not improve outcomes and could cause side effects like low blood pressure or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEURYSMAL SUBARACHNOID HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANEURYSMAL SUBARACHNOID HEMORRHAGE

Contacts and locations

Locations

University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.